Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients With Acute Spinal Cord Injury
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of neurotrauma
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I/II Study of Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients With Acute Spinal Cord Injury: A Double-Blind, Randomized Clinical Trial of Safety and Efficacy
J. Neurotrauma 2020 May 22;[EPub Ahead of Print], N Nagoshi, O Tsuji, K Kitamura, K Suda, T Maeda, Y Yato, T Abe, D Hayata, M Matsumoto, H Okano, M NakamuraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.